+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lumigan 2019 U.S. Promotional Audit Report

  • ID: 5121479
  • Report
  • July 2020
  • 19 pages
  • MD Details
1 of 1
The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Lumigan through reportable promotional activity in 2019 and how does this compare to its peer set in the Glaucoma, Hypotrichosis, and Ocular Hypertension markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Allergan's depth of coverage vary within key specialties (e.g., Ophthalmology and Optometry) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Lumigan throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Lumigan in 2019?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than five years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 15,900 paid interactions across 6,800 physicians made on behalf of Lumigan were carefully examined to support our analysis. In addition, interaction data from 8 peer products (i.e. Alphagan P, Combigan, Rhopressa, Rocklatan, Travatan Z, Vyzulta, Xelpros, and Zioptan) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 1

Loading
LOADING...

Adroll
adroll